Sage Represents Respira Therapeutics - Opportunity to License RT234, A Late Stage Asset for Pulmonar
The Sage Group is working with Respira Therapeutics (“Respira”; http://respiratherapeutics.com/) to identify clinical and commercial development partners for its later stage, highly novel asset for treatment of serious cardiopulmonary disease.
Respira’s initial pipeline is targeting two indications with large unmet medical needs, with market potentials likely in excess of $1Bn each.
Respira is a privately funded US-based company focused on treatment of cardiopulmonary disease using a novel delivery method of its lead compound RT234 (vardenafil) to the small airways of the lungs.Respira's approach combines state-of-the-art proprietary inhaled drug formulation and dry-powder inhaler device technologies, designed to improve lung targeting and dose consistency while maximizing dose delivery to the small airways of the lungs. Respira’s initial pipeline is focused on pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) in patients with interstitial lung disease (ILD-PH).
PAH is a rare, progressive, life-threatening disease and ILD patients with PH have a worsened clinical course and higher mortality than patients with ILD alone.
Respira’s RT234 has received FDA Orphan Drug Designation for use in Pulmonary Arterial Hypertension and is in Phase 2 clinical trials for the first in class, as-needed (PRN) treatment of episodic symptoms in PAH patients.
RT234-PAH has compelling Ph2a data demonstrating hemodynamic mechanism of action and is currently recruiting patients in a Phase 2b study.RT234-PAH has a $1.3Bn addressable market in the US alone, with potential sales estimated at $500M per annum.
The second therapeutic target for RT234 is treatment of the PAH component of patients with ILD and PH (WHO Group 3.2 PH), representing an additional $1Bn market. This is a Phase 2 ready asset (RT234-ILD).
Respira owns all worldwide rights to RT234 in all indications.Respira has strong global IP protection for its RT234 program and approval will be via a 505b2 pathway in the US for both indications.
Respira has appointed The Sage Group to lead its search for a global and/or regional partner(s) to take RT234 through final development and commercialization phases.
About The Sage Group Inc.
The Sage Group Inc. (www.sagehealthcare.com) is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel, China and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million. The establishment of operations in Europe, Japan and China, has allowed its clients to reach out beyond their own regions and capture the potential of the global healthcare market.
The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.
The range of services offered includes:
Strategic alliances and licensing/partnering in and out
M&A, divestment, buy- and sell- side
Global product and technology acquisition searches
Strategic assessment and planning
Due diligence, technology and molecule assessment, valuation
New ventures, interim management
Facilitating investment in R&D and/or company equity through introductions, network and brokering
The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals also have held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.
The Sage Healthcare Group can be contacted at any of the offices shown below:
EU Corporate Office
Dr. Bill Mason
Sage Healthcare Ltd.
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX
UK
Phone: +44 1638 500775 Cell: +44 7785 950134
wtm@sagehealthcare.com
US Corporate Office
Mr. Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North, #381
Clinton, NJ 08809
USA
Phone: + 1 646 4123332
Cell: +1 908 2306170
Fax: +1 908 2319692 wp@sagehealthcare.com
